Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) saw some unusual options trading on Tuesday. Stock investors acquired 562 call options on the company. This is an increase of approximately 981% compared to the typical daily volume of 52 call options.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research downgraded Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. BidaskClub raised Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “strong sell” rating to a “sell” rating in a report on Thursday. Roth Capital set a $14.00 price target on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the stock a “buy” rating in a report on Wednesday. Langenberg & Company reissued a “buy” rating and issued a $30.00 price target (up previously from $27.00) on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in a report on Thursday, September 7th. Finally, Ladenburg Thalmann Financial Services raised their price target on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from $27.00 to $30.00 in a report on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $21.50.

In related news, Director Craig R. Stapleton acquired 140,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were bought at an average price of $8.67 per share, with a total value of $1,213,800.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael S. Anderson acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were bought at an average cost of $8.86 per share, for a total transaction of $44,300.00. The disclosure for this purchase can be found here. 5.07% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Janney Montgomery Scott LLC purchased a new position in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the third quarter worth about $2,100,000. Cubist Systematic Strategies LLC purchased a new position in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the third quarter worth about $184,000. Perceptive Advisors LLC raised its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 8.4% in the third quarter. Perceptive Advisors LLC now owns 1,549,005 shares of the company’s stock worth $16,265,000 after purchasing an additional 119,891 shares during the last quarter. Stonepine Capital Management LLC raised its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 31.7% in the third quarter. Stonepine Capital Management LLC now owns 985,210 shares of the company’s stock worth $10,345,000 after purchasing an additional 237,347 shares during the last quarter. Finally, Trexquant Investment LP raised its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 18.7% in the third quarter. Trexquant Investment LP now owns 36,218 shares of the company’s stock worth $380,000 after purchasing an additional 5,718 shares during the last quarter. 67.75% of the stock is owned by institutional investors and hedge funds.

Shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ AVDL) opened at $8.84 on Friday. The company has a quick ratio of 1.47, a current ratio of 1.53 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $363.56, a PE ratio of 4.58 and a beta of 1.34. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a twelve month low of $7.52 and a twelve month high of $12.30.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.13. The business had revenue of $39.68 million during the quarter, compared to the consensus estimate of $38.22 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a return on equity of 33.92% and a net margin of 44.47%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.08) earnings per share. sell-side analysts forecast that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post 0.35 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Investors Purchase Large Volume of Call Options on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/05/investors-purchase-large-volume-of-call-options-on-avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.